NCT02642809View on ClinicalTrials.gov

Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 8, 2016

Primary Completion Date

September 24, 2020

Study Completion Date

August 3, 2021

Conditions

Esophageal NeoplasmsEsophageal CancerCancer of the Esophagus

Interventions

DRUG

Pembrolizumab

RADIATION

Brachytherapy

PROCEDURE

Endoscopic biopsy

PROCEDURE

Computed tomography-guided biopsy

PROCEDURE

Peripheral blood collection

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02642809 - Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers | Biotech Hunter | Biotech Hunter